Welcome to our dedicated page for Corvus Pharmaceuticals news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a pioneering clinical-stage biopharmaceutical company focused on the development of novel immunotherapies to treat a broad spectrum of cancers and immune diseases. The company's core innovation is the selective inhibition of interleukin-2-inducible T cell kinase (ITK), which plays a crucial role in T cell and natural killer (NK) cell immune functions. Corvus' lead investigational product, soquelitinib (formerly CPI-818), has shown promise in optimizing T cell differentiation and enhancing immune responses against tumors, as well as in the management of autoimmune diseases.
Corvus is advancing soquelitinib through a Phase 3 registrational trial for relapsed peripheral T cell lymphoma (PTCL), an aggressive and typically treatment-resistant form of non-Hodgkin’s lymphoma. The company’s focus on ITK inhibition offers a new therapeutic approach, given the lack of FDA-approved treatments for relapsed PTCL. Soquelitinib has demonstrated the ability to prevent T cell exhaustion and promote the generation of cytotoxic killer T cells, critical in cancer therapy.
In addition, Corvus is investigating soquelitinib for other immune-mediated conditions, including atopic dermatitis. The company recently initiated a randomized, double-blind Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis, aiming to provide an oral treatment alternative to current injectable biologics.
Other promising candidates in Corvus' pipeline include ciforadenant, an adenosine A2A receptor inhibitor that disables tumors' immune evasion mechanisms, and mupadolimab, a monoclonal antibody targeting CD73. These candidates are being studied for their efficacy in combination therapies for various cancers, including head and neck cancers and non-small cell lung cancer.
Financially, Corvus maintains a strong position, having raised significant capital through direct offerings to support its clinical trials and operational needs. With cash reserves projected to fund operations into late 2025, Corvus is well-positioned to achieve substantial milestones in its clinical programs. The company continues to foster critical partnerships, including collaborations with Angel Pharmaceuticals for the Chinese market.
Latest news highlights Corvus' progress in clinical trials and strategic financing moves, underscoring its commitment to bringing innovative immunotherapies to patients in need. For more information, visit the Corvus Pharmaceuticals website.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced the approval of its partner Angel Pharmaceuticals' IND application to initiate a Phase 1/1b clinical trial for CPI-818 in relapsed/refractory T-cell lymphomas in China. Corvus holds a 49.7% equity stake in Angel Pharma, responsible for all development costs. CPI-818 is the only clinical-stage ITK-inhibitor in China and has shown promising interim results in earlier trials. The initiative aligns with Corvus’ strategy to enhance global product development, addressing a significant healthcare need in China.
Angel Pharmaceuticals announced the approval of its IND application for CPI-818, a unique ITK inhibitor, by the Center for Drug Evaluation in China. This drug targets relapsed/refractory T-cell lymphomas and is the only ITK inhibitor in clinical development. CPI-818 has shown promising anti-tumor activity and is currently in a multi-center Phase 1b/2 trial in the U.S. and Asia. The collaboration with Corvus Pharmaceuticals provides Angel with the rights to develop and commercialize CPI-818 in China, presenting a crucial step in addressing the unmet need for effective treatments in this patient population.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced positive results from a COVID-19 randomized controlled study involving 40 patients treated with mupadolimab, showing improved primary and secondary endpoints compared to placebo. The Phase 3 trial, though discontinued voluntarily, indicated a potential dose-response effect, particularly at 2mg/kg, with no reported adverse events. The company is also conducting a Phase 1b/2 trial for mupadolimab in oncology, with data expected to be presented at the SITC meeting in November.
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company (NASDAQ: CRVS), announced participation in two investor conferences in September 2021. The first event, the H.C. Wainwright Annual Global Investment Conference, is set for September 13-15, where CEO Richard A. Miller will offer a pre-recorded presentation available starting September 13 at 7:00 am ET. The second event, the Cantor Virtual Global Healthcare Conference, runs from September 27-30, with Dr. Miller presenting on September 29 from 3:20-3:50 pm ET. Webcast replays will be accessible for 90 days post-event.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced that its partner, Angel Pharmaceuticals, received approval for a Phase 1/1b clinical trial of CPI-818 in China for T cell lymphomas. This milestone, expected to initiate by year-end 2021, underscores Corvus’ global growth strategy. CPI-818, an ITK inhibitor, shows potential in treating T cell malignancies, with interim trial results demonstrating significant tumor responses. Additionally, Angel Pharma launched new R&D centers in China and the U.S., enhancing its capabilities in drug development.
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) reported its Q2 2021 financial results, revealing cash reserves of $66.5 million, up from $44.3 million at year-end 2020. The company continues to develop mupadolimab for HPV+ head and neck cancer and other viral-related cancers, having begun a Phase 1b/2 trial. Corvus discontinued its Phase 3 COVID-19 trial, reducing expected 2021 operating cash use to $35-$37 million, down from $46-$48 million. R&D expenses rose to $9.1 million, resulting in a net loss of $11.8 million for the quarter.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced the discontinuation of its Phase 3 study of mupadolimab for COVID-19, citing successful vaccine trends. The company will focus on oncology, particularly for HPV+ head and neck cancer, where mupadolimab is in an ongoing Phase 1/1b trial. Initial evidence suggests its effectiveness in enhancing immune responses. Additionally, Corvus reduced its projected 2021 net cash used in operating activities by $11 million, now estimating between $35-37 million. The company had $66.5 million in cash as of June 30, 2021.
BURLINGAME, Calif., May 25, 2021 – Corvus Pharmaceuticals (NASDAQ: CRVS) will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, from 4:00-4:25 pm ET. The presentation will be available via live webcast and accessible for 30 days afterwards through the investor relations section of Corvus' website.
Corvus focuses on developing innovative therapies, with lead candidate mupadolimab in Phase 3 trials for COVID-19 and ongoing studies for T-cell lymphomas. For detailed information, visit www.corvuspharma.com.
Corvus Pharmaceuticals (NASDAQ:CRVS) announced the completion of a $10 million common share sale through its ATM program, with 3,564,228 shares sold to EcoR1 Capital and 35,714 shares to CEO Richard A. Miller at $2.80 per share. The settlement is set for May 6, 2021. This follows an effective shelf registration statement declared on March 19, 2020. Investors are encouraged to review the related prospectus available on the SEC's EDGAR database or by contacting Jefferies LLC directly. The company is focused on advancing its clinical programs, including CPI-006 and CPI-818.
Corvus Pharmaceuticals (Nasdaq: CRVS) provided a business update and reported Q1 2021 financial results. The company is advancing its Phase 3 trial for CPI-006 in hospitalized COVID-19 patients, with full enrollment expected by year-end. Financially, Corvus reported cash and equivalents of $68 million, up from $44.3 million in Q4 2020, aided by a $32 million equity offering. R&D expenses decreased to $8.2 million, while the net loss narrowed to $11.6 million. Corvus is also progressing with CPI-818 and ciforadenant clinical trials, showcasing potential in cancer treatments.
FAQ
What is the current stock price of Corvus Pharmaceuticals (CRVS)?
What is the market cap of Corvus Pharmaceuticals (CRVS)?
What is Corvus Pharmaceuticals' lead product candidate?
What conditions is Corvus Pharmaceuticals targeting with soquelitinib?
What is the significance of ITK inhibition in Corvus Pharmaceuticals' research?
What other products are in Corvus Pharmaceuticals' pipeline?
What recent financial developments have supported Corvus Pharmaceuticals' research?
What is the background of Corvus Pharmaceuticals?
What partnerships does Corvus Pharmaceuticals have?
How is Corvus Pharmaceuticals addressing the unmet needs in relapsed PTCL?
How is soquelitinib being evaluated for atopic dermatitis?
What makes mupadolimab unique in Corvus Pharmaceuticals' research?
